Format

Send to

Choose Destination
Oncotarget. 2016 Nov 22;7(47):77358-77364. doi: 10.18632/oncotarget.12669.

GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients.

Author information

1
Centre de Recherche en Cancérologie de Lyon, INSERM U1052 - Centre Léon Bérard, 69373 Lyon, France.
2
Hôpital Jean-Minjoz, Centre Hospitalier Universitaire, Boulevard Fleming, 25030 Besançon, France.
3
Oncologie Sénologie, ICM Institut Régional du Cancer, 34298 Montpellier Cedex, France.
4
Georges-François Leclerc, 21000 Dijon, France.
5
Institut de Cancérologie de Lorraine - Alexis Vautrin, Département d'Oncologie Médicale, 54511 Vandœuvre-lès-Nancy Cedex, France.
6
Institut Bergonié, Département d'Oncologie Médicale, 33000 Bordeaux, France.
7
Centre Léon Bérard, Département de Cancérologie Médicale, Lyon Cedex 08, France.
8
Institut de Cancérologie de l'Ouest, Service Oncologie Médicale, 49993 Angers Cedex 09, France.
9
Institut Jean Godinot, Service Oncologie Médicale, 51056 Reims Cedex, France.
10
Clinique Victor Hugo-Centre Jean Bernard, 72015 Le Mans Cedex 2, France.
11
Centre Paul Strauss, Service d'Oncologie Médicale, 67065 Strasbourg Cedex, France.
12
Centre Henri Becquerel, rue d'Amiens, 76038 Rouen, France.
13
Institut Daniel Hollard, Service Oncologie Médicale, 38028 Grenoble Cedex 01, France.
14
Institut Gustave Roussy, Comité de Pathologie Mammaire, 94805 Villejuif Cedex, France.
15
Institut de Cancérologie Lucien Neuwirth, Service Oncologie Médicale, 42270 Saint Priest en Jarez, France.
16
Centre Hospitalier de Limoges, Service d'Oncologie Médicale, 87042 Limoges Cedex, France.
17
Clinique Drévon, Centre d'Oncologie et de Radiothérapie du Parc, 21000 Dijon, France.
18
Centre Antoine Lacassagne, Département Oncologie Médicale, 06189 Nice Cedex 02, France.
19
Institut Paoli-Calmettes, Département d'Oncologie Médicale, 13009 Marseille, France.
20
Centre François Baclesse, 14076 Caen Cedex 5, France.
21
Pôle Mutualiste, Service Oncologie Médicale, 44606 Saint Nazaire, France.
22
Centre Hospitalier Lyon Sud, Service d'Oncologie Médicale, 69495 Pierre-Benite cedex, France.
23
Centre Hospitalier Le Mans, Service d'Onco-Hématologie et Médecine interne, 72037 Le Mans Cedex, France.
24
Centre Hospitalier Régional d'Orléans, Service d'Oncologie Médicale, 45032 Orleans Cedex 1, France.
25
Institut Curie, Department of Medical Oncology, 75248 Paris Cedex 05, France.
26
Institut National du Cancer, Direction de la Recherche, 92513 Boulogne-Billancourt, France.
27
Fondation Jean Dausset, Centre d'Etudes du Polymorphisme Humain, 75010 Paris, France.
28
Centre National du Génotypage, Institut de Génomique, CEA, CP 5721, 91057 Evry Cedex, France.
29
Synergie Lyon Cancer, Centre Léon Bérard, Lyon Cedex 08, France.

Abstract

Genetic polymorphisms are associated with breast cancer risk. Clinical and epidemiological observations suggest that clinical characteristics of breast cancer, such as estrogen receptor or HER2 status, are also influenced by hereditary factors. To identify genetic variants associated with pathological characteristics of breast cancer patients, a Genome Wide Association Study was performed in a cohort of 9365 women from the French nationwide SIGNAL/PHARE studies (NCT00381901/RECF1098). Strong association between the FGFR2 locus and ER status of breast cancer patients was observed (ER-positive n=6211, ER-negative n=2516; rs3135718 OR=1.34 p=5.46×10-12). This association was limited to patients with HER2-negative tumors (ER-positive n=4267, ER-negative n=1185; rs3135724 OR=1.85 p=1.16×10-11). The FGFR2 locus is known to be associated with breast cancer risk. This study provides sound evidence for an association between variants in the FGFR2 locus and ER status among breast cancer patients, particularly among patients with HER2-negative disease. This refinement of the association between FGFR2 variants and ER-status to HER2-negative disease provides novel insight to potential biological and clinical influence of genetic polymorphisms on breast tumors.

KEYWORDS:

GWAS; HER2; association; breast; estrogen receptor

PMID:
27764800
PMCID:
PMC5363591
DOI:
10.18632/oncotarget.12669
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center